ABRAMS'dCLINICALdDRUGdTHERAPY:dRATIONALESdFORdNURSINGdPRACTICE
,ABRAMS'dCLINICALdDRUGdTHERAPY:dRATIONALESdFORdNURSINGdPRACTICE
,ABRAMS'dCLINICALdDRUGdTHERAPY:dRATIONALESdFORdNURSINGdPRACTICE
, ABRAMS'dCLINICALdDRUGdTHERAPY:dRATIONALESdFORdNURSINGdPRACTICE
Chapter 1, The Foundation of Pharmacology: Quality and Safety
d d d d d d d d
1. Adwomanddiagnoseddwithdobsessive–
compulsiveddisorderdhasdbeendprescribeddorald paroxetinedhydrochloride.dWhatd isdth
edexpecteddeffectd fordthisdprescription?
A. Curativedeffectdondsymptoms
B. Systemicdeffectdondsymptoms
C. Localdeffectdondsymptoms
D. Parenteraldeffectdondsymptoms
ANS:ddB
Rationale:dDrugsdthatdproducedsystemicdeffectsdaredtakendintodthedbody,dcirculateddthroughd the
dbloodstreamdtodtheirdsitesdofdactiondindvariousd bodydtissues,d anddeventuallydeliminatedd fromdth
edbody.dCurativedagentsdaredgivendtodcuredaddiseasedprocess.dIndthisdcase,dparoxetined hydrochl
oridedwilldcontroldthedsymptomsdbutd notdcuredtheddisorder.dDrugsdwithdlocaldeffects,d suchdasdsunsc
reendanddlocaldanesthetics,dactdmainlydatdthedsitedofdapplication.d Paroxetined hydrochloridedisdn
otdadministereddparenterally.dParenteraldagentsdaredadministeredd subcutaneously,d intramuscul
arly,dordintravenously.
PTS: 1 REF: p.d3,dIntroduction OBJ: 1
NAT:d ClientdNeeds:dPhysiologicaldIntegrity:dPharmacologicaldanddParenteraldTherapiesd T
OP: Chapter:d1:dThedFoundationdofdPharmacology:d QualitydanddSafety
KEY:d IntegrateddProcess:dNursingdProcess
BLM:dd CognitivedLevel:dUnderstand NOT:d MultipledChoice
2. Adclientdhasdbeendprescribeddandantibiotic.dThisdmedicationdisdadnaturallydoccurring
substancedthatdhasdbeendcheGmRicA
alDlyEm
SoBdOifOieSd.TWhaOtdM
.C isdanotherdnamedfordthisdtypedofdmedication?
A. Syntheticddrug
B. Semisyntheticddrug
C. Biotechnologyddrug
D. Prototypeddrug
ANS:ddB
Rationale:dSemisyntheticddrugsd(e.g.,dmanydantibiotics)dared naturallydoccurringdsubstancesd thatd
havedbeendchemicallydmodified.dSyntheticddrugsdaredmoredstandardizeddindtheirdchemicald chara
cteristics,d moredconsistentdindtheirdeffects,danddlessdlikelydtodproducedallergicdreactions.d Biotechn
ologyddrugsdinvolvedmanipulatingdDNAdanddRNAdanddrecombiningdgenesdintod hybriddmolecules
dthatd candbed inserteddintodlivingdorganisms.d Prototypeddrugsdaredthedfirstd drugdofdadparticulard g
roupdtodbeddeveloped.
PTS: 1 REF: p.d3,dDrugdSources OBJ: 1
NAT:d ClientdNeeds:dPhysiologicaldIntegrity:dPharmacologicaldanddParenteraldTherapiesd T
OP: Chapter:d1:dThedFoundationdofdPharmacology:dQualitydanddSafety
KEY:d IntegrateddProcess:dNursingdProcess
BLM:dd CognitivedLevel:dUnderstand NOT:d MultipledChoice
3. Whichdclassificationdappliesdtodmorphine?
A. Centraldnervousdsystemddepressant
B. Centraldnervousdsystemdstimulant
ABRAMS'dCLINICALdDRUGdTHERAPY:dRATIONALESdFORdNURSINGdPRACTICE
,ABRAMS'dCLINICALdDRUGdTHERAPY:dRATIONALESdFORdNURSINGdPRACTICE
,ABRAMS'dCLINICALdDRUGdTHERAPY:dRATIONALESdFORdNURSINGdPRACTICE
, ABRAMS'dCLINICALdDRUGdTHERAPY:dRATIONALESdFORdNURSINGdPRACTICE
Chapter 1, The Foundation of Pharmacology: Quality and Safety
d d d d d d d d
1. Adwomanddiagnoseddwithdobsessive–
compulsiveddisorderdhasdbeendprescribeddorald paroxetinedhydrochloride.dWhatd isdth
edexpecteddeffectd fordthisdprescription?
A. Curativedeffectdondsymptoms
B. Systemicdeffectdondsymptoms
C. Localdeffectdondsymptoms
D. Parenteraldeffectdondsymptoms
ANS:ddB
Rationale:dDrugsdthatdproducedsystemicdeffectsdaredtakendintodthedbody,dcirculateddthroughd the
dbloodstreamdtodtheirdsitesdofdactiondindvariousd bodydtissues,d anddeventuallydeliminatedd fromdth
edbody.dCurativedagentsdaredgivendtodcuredaddiseasedprocess.dIndthisdcase,dparoxetined hydrochl
oridedwilldcontroldthedsymptomsdbutd notdcuredtheddisorder.dDrugsdwithdlocaldeffects,d suchdasdsunsc
reendanddlocaldanesthetics,dactdmainlydatdthedsitedofdapplication.d Paroxetined hydrochloridedisdn
otdadministereddparenterally.dParenteraldagentsdaredadministeredd subcutaneously,d intramuscul
arly,dordintravenously.
PTS: 1 REF: p.d3,dIntroduction OBJ: 1
NAT:d ClientdNeeds:dPhysiologicaldIntegrity:dPharmacologicaldanddParenteraldTherapiesd T
OP: Chapter:d1:dThedFoundationdofdPharmacology:d QualitydanddSafety
KEY:d IntegrateddProcess:dNursingdProcess
BLM:dd CognitivedLevel:dUnderstand NOT:d MultipledChoice
2. Adclientdhasdbeendprescribeddandantibiotic.dThisdmedicationdisdadnaturallydoccurring
substancedthatdhasdbeendcheGmRicA
alDlyEm
SoBdOifOieSd.TWhaOtdM
.C isdanotherdnamedfordthisdtypedofdmedication?
A. Syntheticddrug
B. Semisyntheticddrug
C. Biotechnologyddrug
D. Prototypeddrug
ANS:ddB
Rationale:dSemisyntheticddrugsd(e.g.,dmanydantibiotics)dared naturallydoccurringdsubstancesd thatd
havedbeendchemicallydmodified.dSyntheticddrugsdaredmoredstandardizeddindtheirdchemicald chara
cteristics,d moredconsistentdindtheirdeffects,danddlessdlikelydtodproducedallergicdreactions.d Biotechn
ologyddrugsdinvolvedmanipulatingdDNAdanddRNAdanddrecombiningdgenesdintod hybriddmolecules
dthatd candbed inserteddintodlivingdorganisms.d Prototypeddrugsdaredthedfirstd drugdofdadparticulard g
roupdtodbeddeveloped.
PTS: 1 REF: p.d3,dDrugdSources OBJ: 1
NAT:d ClientdNeeds:dPhysiologicaldIntegrity:dPharmacologicaldanddParenteraldTherapiesd T
OP: Chapter:d1:dThedFoundationdofdPharmacology:dQualitydanddSafety
KEY:d IntegrateddProcess:dNursingdProcess
BLM:dd CognitivedLevel:dUnderstand NOT:d MultipledChoice
3. Whichdclassificationdappliesdtodmorphine?
A. Centraldnervousdsystemddepressant
B. Centraldnervousdsystemdstimulant
ABRAMS'dCLINICALdDRUGdTHERAPY:dRATIONALESdFORdNURSINGdPRACTICE
